Company intelligence / Profile preview

SineuGene Therapeutics

Changping District, Beijing, Chinasineugene.com ↗

Ownership: Private
Development stage: Phase 1

Overview

SineuGene has received FDA IND clearance for its lead candidate SNUG01, a first-in-class TRIM72-targeted gene therapy for ALS. The company has initiated a global Phase I/IIa trial to evaluate safety, tolerability, and preliminary efficacy via intrathecal administration of rAAV9-hTRIM72. Preclinical data support the neuroprotective role of TRIM72 identified by Dr. Yichang Jia’s lab at Tsinghua University.

Therapeutic areas: Neurology
Modalities: Gene therapy (AAV-based)
Industry: Biotech

Drug pipeline

6 assets

SNUG01

5 more assets in the full pipeline.

Partnerships

Collaboration with PackGene (Guangzhou) to screen new AAV serotypes for CNS applications.

Beyond the preview

Go deeper on SineuGene Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SineuGene Therapeutics.